In the near future, the antibody specialist MorphoSys in Martinsried expects clinical results about its proprietary development candidates MOR 103, an antibody that is directed against the target molecule of GM-CSF. The therapeutic antibody is currently tested in a phase 1b/2a trial against the inflammatory autoimmune disease rheumatoid arthritis.
So that the wait doesn’t seem too long, two recent studies of MorphoSys and the University of Melbourne underline the importance of the target molecule GM-CSF in inflammatory pain including arthritic pain.
The fully human HuCAL antibody MOR103 is the most advanced proprietary development candidate of the company MorphoSys and is being developed for the indications rheumatoid arthritis and multiple sclerosis. The studies suggest that the antibody could also be effective against other inflammatory disorders such as osteoarthritis.
To the press release of MorphoSys